BIOYF:OTC-BioSyent Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 5.49

Change

+0.08 (+1.48)%

Market Cap

USD 0.07B

Volume

1.10K

Average Target Price

USD 7.00 (+27.50%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells and is indicated for the prevention of iron deficiency anemia; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains. BioSyent Inc. sells its products number of wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Mississauga, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

-0.44 (-1.40%)

USD68.21B 29.93 16.44
MKGAF MERCK Kommanditgesellschaft au..

-0.75 (-0.49%)

USD67.07B 29.96 16.44
TKPHF Takeda Pharmaceutical Company ..

N/A

USD54.94B 102.56 0.13
ESALF Eisai Co., Ltd

N/A

USD21.36B 18.29 0.12
ESALY Eisai Co., Ltd

-0.70 (-0.94%)

USD21.32B 18.55 0.12
SFOSF Shanghai Fosun Pharmaceutical ..

-0.19 (-4.24%)

USD19.05B 19.44 3.45
SGIOY Shionogi & Co., Ltd

+0.05 (+0.37%)

USD16.81B 14.59 0.07
SGIOF Shionogi & Co., Ltd

+1.25 (+2.37%)

USD16.45B 14.50 0.07
TEVJF Teva Pharmaceutical Industries..

N/A

USD10.56B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing BIOYF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.09% 68% D+ 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.09% 67% D+ 65% D
Trailing 12 Months  
Capital Gain 15.58% 68% D+ 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.58% 68% D+ 63% D
Trailing 5 Years  
Capital Gain 4.37% 66% D 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.37% 65% D 50% F
Average Annual (5 Year Horizon)  
Capital Gain -3.44% N/A N/A 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.44% N/A N/A 30% F
Risk Return Profile  
Volatility (Standard Deviation) 26.22% N/A N/A 62% D-
Risk Adjusted Return -13.13% N/A N/A 33% F
Market Capitalization 0.07B 80% B- 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.31 28% F 40% F
Price/Book Ratio 3.51 29% F 30% F
Price / Cash Flow Ratio 14.78 7% F 11% F
EV/EBITDA 7.56 37% F 38% F
Management Effectiveness  
Return on Equity 19.54% 94% A 90% A-
Return on Invested Capital 14.56% 77% C+ 77% C+
Return on Assets 14.23% 98% A+ 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.16 47% F 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.